This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Simon Benito Biography and Net Worth

Director of DURECT

Currently, Simon X. Benito holds the position of Chairman for Inovio Pharmaceuticals, Inc. Mr. Benito is also on the board of DURECT Corp.

In his past career he held the position of Senior Vice President-Vaccine Division at Merck & Co., Inc. Executive Vice President of Merck-Medco Managed Care LLC and Executive Director & Vice President at Merck Human Health US (both are subsidiaries of Merck & Co., Inc.).

What is Simon X. Benito's net worth?: The estimated net worth of Simon X. Benito is at least $478.10 as of July 20th, 2022. Mr. Benito owns 522 shares of DURECT stock worth more than $478 as of April 25th. This net worth approximation does not reflect any other investments that Mr. Benito may own. Learn More about Simon X. Benito's net worth.
How do I contact Simon X. Benito?: The corporate mailing address for Mr. Benito and other DURECT executives is 10260 BUBB RD, CUPERTINO CA, 95014. DURECT can also be reached via phone at (408) 777-1417 and via email at [email protected]. Learn More on Simon X. Benito's contact information.
Has Simon X. Benito been buying or selling shares of DURECT?: Simon X. Benito has not been actively trading shares of DURECT within the last three months. Most recently, on Tuesday, December 7th, Simon X. Benito bought 20,000 shares of DURECT stock. The stock was acquired at an average cost of $1.02 per share, with a total value of $20,400.00. Learn More on Simon X. Benito's trading history.
Who are DURECT's active insiders?: DURECT's insider roster includes Simon Benito (Director), and Judy Joice (VP). Learn More on DURECT's active insiders.

Simon X. Benito Insider Trading History at DURECT

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/7/2021	Buy	20,000	$1.02	$20,400.00
3/10/2015	Buy	40,000	$1.81	$72,400.00

Simon X. Benito Buying and Selling Activity at DURECT

DURECT Company Overview

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Today's Range

Now: $0.92

$0.87

$0.92

50 Day Range

MA: $1.03

$0.77

$1.37

2 Week Range

Now: $0.92

$0.47

$7.46

Volume

33,643 shs

Average Volume

186,239 shs

Market Capitalization

$28.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad